Effects of etelcalcetide and cinacalcet for the vascular carcification in hemodialysis patients with secondary hyperparathyroidism

Effects of etelcalcetide and cinacalcet for the vascular carcification in hemodialysis patients with secondary hyperparathyroidism - Effects of etelcalcetide and cinacalcet for the vascular carcification

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027454

Enrollment

Registered

2017-05-23

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients complicated with secondary hyperparathyroidism

Interventions

etelcalcetide 2.5 - 15mg/ hemodialysis session cinacalcet 12.5 - 100 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance hemodialysis patients with secondary hyperparathyroidism whose iPTH levels are higher than 240pg/ml despite the administration of maxacalcitol 2.5-5 micro g/every hemodialysis session.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
Changes of ABI and PWV, IMT (carotid ultrasound) ACI and ACAI (abdominal CT) 12 months	—

Secondary

Measure	Time frame
Ca, P, iPTH	—

Countries

Japan

Contacts

Public ContactTakahiro Yajima

Matsunami general hospital Department of Nephrology

yajima5639@gmail.com058-388-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026